Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors

Acta Oncol. 2023 Nov;62(11):1440-1450. doi: 10.1080/0284186X.2023.2259597. Epub 2023 Nov 7.

Abstract

Purpose: To evaluate the persistence of symptoms after radiotherapy (RT) for localised prostate cancer (PCa) and the association with quality of life (QOL).

Materials and methods: Prospective patient-reported outcome (PRO) from a multi-institutional study on PCa treated with radical RT (2010-2014) was analysed. Data was collected at baseline (BL) and follow-ups (FUPs) up to 5 years. Patients with BL and ≥3 late FUPs (≥6 months) were analysed. PRO was scored by means of the IPSS and ICIQ-SF (urinary), LENT-SOMA (gastrointestinal [GI]), and EORTC-C30 (pain, insomnia, fatigue, and QOL) questionnaires. Symptoms were defined 'persistent' if the median score over FUPs was ≥3 (urinary) or ≥2 (GI, pain, insomnia, and fatigue), and worse than BL. Different thresholds were chosen to have enough events for each symptom. QOL was linearly transformed on a continuous scale (0-100). Linear-mixed models were used to identify significant differences between groups with and without persistent symptoms including age, smoking status, previous abdominal surgery, and diabetes as confounders. Mean QOL differences between groups were evaluated longitudinally over FUPs.

Results: The analysis included 293 patients. Persistent urinary symptoms ranged from 2% (straining) to 12% (weak stream, and nocturia). Gastrointestinal symptoms ranged from 7% (rectal pain, and incontinence) to 30% (urgency). Proportions of pain, insomnia, and fatigue were 6, 13, and 18%. Significant QOL differences of small-to-medium clinical relevance were found for urinary incontinence, frequency, urgency, and nocturia. Among GI symptoms, rectal pain and incontinence showed small-to-medium differences. Fatigue was associated with the largest differences.

Conclusions: The analysis showed that symptoms after RT for PCa occur with different persistence and their association with QOL varies in magnitude. A number of persistent urinary and GI symptoms showed differences in a comparable range. Urinary incontinence and frequency, rectal pain, and faecal incontinence more often had significant associations. Fatigue was also prevalent and associated with largely deteriorated QOL.

Keywords: clinical study; prostate cancer; quality of life; radiotherapy; side effects.

MeSH terms

  • Cancer Survivors*
  • Fatigue
  • Gastrointestinal Diseases*
  • Humans
  • Male
  • Nocturia* / complications
  • Pain
  • Prospective Studies
  • Prostate
  • Prostatic Neoplasms* / radiotherapy
  • Quality of Life
  • Rectal Diseases*
  • Sleep Initiation and Maintenance Disorders*
  • Surveys and Questionnaires
  • Urinary Incontinence* / complications